Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer

5th September 2019 Uncategorised 0

Bristol-Myers Squibb has come up empty-handed in one of the world’s deadliest cancers. Adding Opdivo to standard-of-care treatment failed to significantly cut the risk of disease worsening or death in newly diagnosed glioblastoma patients.

More: Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer
Source: fierce